The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Orexigen Therapeutics Inc

Nasdaq: OREX
Last

(U.S.) $1.85

Today's change-0.09 -4.64%
Updated December 7 1:48 PM EST. Delayed by at least 15 minutes.
 

Orexigen Therapeutics Inc

Nasdaq: OREX
Last

(U.S.) $1.85

Today's change-0.09 -4.64%
Updated December 7 1:48 PM EST. Delayed by at least 15 minutes.

Orexigen Therapeutics Inc down (U.S.)$0.09

Orexigen Therapeutics Inc is sharply lower today, dropping (U.S.)$0.09 or 4.64% to (U.S.)$1.85. Over the last five days, shares have lost 5.61% and are down 89.24% for the last year to date. This security has underperformed the S&P 500 by 97.63% during the last year.

Key company metrics

  • Open(U.S.) $1.91
  • Previous close(U.S.) $1.94
  • High(U.S.) $1.92
  • Low(U.S.) $1.84
  • Bid / Ask(U.S.) $1.85 / (U.S.) $1.86
  • YTD % change-89.24%
  • Volume76,200
  • Average volume (10-day)159,880
  • Average volume (1-month)137,194
  • Average volume (3-month)143,619
  • 52-week range(U.S.) $1.75 to (U.S.) $20.30
  • Beta3.00
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$3.19
Updated December 7 1:48 PM EST. Delayed by at least 15 minutes.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2016Q2/2016Q1/2016Q4/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016Dec 31, 201512/31/2015
Revenue7855
Total other revenue--------
Total revenue7855
Gross profit56----
Total cost of revenue22----
Total operating expense-36412818
Selling / general / administrative35251712
Research & development514126
Depreciation / amortization1------
Interest expense (income), net operating--------
Unusual expense (income)1------
Other operating expenses, total-80------
Operating income43-33-23-13
Interest income (expense), net non-operating-2-2-2-2
Gain (loss) on sale of assets--------
Other--------
Income before tax48-25-22-16
Income after tax48-25-22-18
Income tax, total------1
Net income48-25-22-18
Total adjustments to net income--------
Net income before extra. items48-25-22-18
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items48-25-22-18
Inc. avail. to common incl. extra. items48-25-22-18
Diluted net income48-25-22-18
Dilution adjustment--------
Diluted weighted average shares37151515
Diluted EPS excluding extraordinary itemsvalue per share1.30-1.73-1.54-1.22
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share1.33-1.73-1.54-1.22